Highlighted results for ovarian cancer patients include differential interpatient sensitivities and similar response for multiple intrapatient sample sites.
KYAN Technologies will present at the 15th Biennial Ovarian Cancer Research Symposium, hosted by The Rivkin Center for Ovarian Cancer and the American Association for Cancer Research (AACR). The symposium is scheduled to take place in Seattle, USA, on September 20-21, 2024.
Details related to the poster presentations are as follows:
Title: Utilizing Optim.AI combinatorial functional precision medicine platform to predict treatment options for ovarian cancer
Poster Number: P95
Session: Poster Session #1 and Reception
Session Date: Friday, September 20, 2024
Session Time: 6:00 PM – 9:00 PM
Presenter and KYAN’s Chief Scientific Officer, Dr. Edward Chow, Ph.D., commented, “This study provides early evidence that Optim.AI™ can be successfully performed on cryopreserved ovarian cancer samples to predict treatment response to platinum-based treatments as well as other combination-based alternatives. Even more exciting is paired analysis comparing cancer cells from the primary tumor compared to ascites fluid revealed matching Optim.AI™ results, suggesting that Optim.AI™ may work with less invasive biopsy samples.”
KYAN has successfully performed its Optim.AI™ test across more than 14 solid cancer types. The study with University of Basel has further enhanced KYAN’s growing experience and data generation.